NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Ocular Therapeutix, Inc. (OCUL) Stock Analysis

Ocular Therapeutix, Inc. (OCUL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

OCUL

$10.64

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OCUL with… →

OCUL Key Statistics

As of Sep 4, 2026
Trading
Open
$10.51
Previous Close
$10.64
Day's Range
10.51–10.77
52-Week Range
6.23–16.44
Volume
1.31M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.97
Valuation
Market Cap
$2.34B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
44.89
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.40
Financials (FY)
Revenue (FY)
$51.95M−18.47%
Net Income (FY)
−$265.94M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
219.62M
1-Year Return
−16.22%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
2.66M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

OCUL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−12.36%
2025+42.15%
2024+91.48%
2023+58.72%
2022−59.68%
2021−66.33%
2020+424.05%
2019−0.75%
2018−10.56%
2017−46.83%
2016 (partial year)+36.99%

As of September 4, 2026.

OCUL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$51.95M−$265.94M−511.9%
2024$63.72M−$193.51M−303.7%
2023$58.44M−$80.74M−138.1%
2022$51.49M−$71.04M−138.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$51.95M$45.38M−$270.02M−$265.94M−511.9%
2024$63.72M$58.10M−$171.78M−$193.51M−303.7%
2023$58.44M$53.16M−$82.38M−$80.74M−138.1%
2022$51.49M$46.95M−$78.65M−$71.04M−138.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OCUL Valuation vs Biotechnology Median

Median of 656 stocks
MetricOCULBiotechnology medianvs median
P/S ratio44.8915.26194% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Ocular Therapeutix, Inc. (OCUL) at $2.34B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 325.

The 52-week range on file runs from $6.23 to $16.44. The most recent close on file for OCUL is $10.64, dated September 4, 2026. The close was unchanged from the previous session. The latest close sits 70.79% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $51.95M. Against the prior fiscal year total of $63.72M, that is a change of −18.47%. The same year closed with a net loss of $265.94M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.4.

Across the 4 fiscal years on file, revenue moves from $51.49M in 2022 to $51.95M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 44.89 times revenue. On price-to-sales that is 194.09% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −16.22%. Measured over 10 years, that is +5.25% a year compounded. Beta against the wider market is reported at 0.97. Annualized volatility over the trailing 10 years is 77.14%.

Growth & Income

The record shows no dividend for OCUL.

So far in 2026 the price is −12.36%. Across the complete calendar years on file, 2020 returned +424.05% and 2021 returned −66.33%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Ocular Therapeutix, Inc. (OCUL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Ocular Therapeutix, Inc. OCUL $2.34B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Ocular Therapeutix, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Visit website →